ClinicalTrials.gg
Enrolling by invitationNCT06042621TIMEUpdated Feb 5, 2026

A Study of Communication Between Clinicians, Patients, and Families in the Intensive Care Unit (ICU)

An observational study in Acute Respiratory Failure, Mechanical Ventilation and Life-Supporting Treatments, sponsored by University of Wisconsin, Madison. Enrolling by invitation at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by University of Wisconsin, Madison · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7,818
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Communication by University of Wisconsin, Madison — 6 open to participants now, 7 under way, none of them phase 3. Communication · University of Wisconsin, Madison.

Started
2024
with 2 others
Observational
4 of 16
3 open now
Registered
11th of 16
by date

Among the 16 studies in Communication by University of Wisconsin, Madison, this one is one of 3 that started in 2024, is one of 4 observational ones, and was the 11th registered.

Communication

720 studies on the registry are indexed under Communication; 160 are open to participants now.

Browse Communication studies →

Open to participants now

6 of the 16 studies in Communication by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 88 Communication studies recruiting now, 53 (60%) set no upper age limit and 28 (32%) stop at 75 or younger; 32 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Communication by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

The purpose of this study is to investigate a specific approach to patient care called a time-limited trial (TLT). This approach is sometimes used for people who develop critical illness and are cared for in an intensive care unit (ICU). A time-limited trial is a plan made together by medical teams, patients with critical illness (if they can take part), and their families or other important people helping to make their healthcare decisions. A time-limited trial starts with a discussion of the patient's goals and wishes. Then, a plan is made to use ICU treatments for a set period of time to give the patient the chance to recover. After this time, the patient's response to treatment will be reviewed to help guide what to do next.

Medical teams consider this kind of plan when it is not clear if a patient can recover to a quality of life that is acceptable to them. With a time-limited trial, patients, families, and medical teams experience this uncertainty together.

The main goal of this study is to find the best way to use TLTs for patients in the ICU who have trouble breathing and need mechanical ventilation to help them breathe. The hypothesis is that optimal time-limited trial delivery will reduce the time patients with acute respiratory failure spend in the ICU and will improve the intensive care unit experiences for their families and clinicians.

Read the detailed description

This is a multi-site observational study that will investigate the time-limited trial approach to care for patients with critical illness, which is a trial of life support with milestones and a timeline to help evaluate whether the patient is improving. The primary objective of this study is to define the optimal care delivery processes of a time-limited trial for adult intensive care unit (ICU) patients who develop acute respiratory failure requiring mechanical ventilation. The two aims of this study are to:

Aim 1: Map the current processes of time-limited trial care delivery for patients with acute respiratory failure.

Aim 2: Elucidate the relationships between time-limited trials, their care delivery processes, and end-of-life outcomes for patients, surrogates, and ICU teams.

For Aim 1, a focused ethnography of approximately 50 time-limited trials will be done to characterize how trials are currently being done in the intensive care unit. This will include direct observation of ICU care provided to patients and real-time interviews with their surrogates and the ICU team members providing their care. Qualitative analyses will be used to characterize TLT activities and team member roles. This data will support the construction of a systems engineering process map, which is a visual tool that diagrams the sequence of process steps and serves as a time-limited trial process measure.

For Aim 2, a prospective cohort of 5,810 patients with acute respiratory failure will be followed to evaluate relationships between time-limited trial exposure and ICU outcomes through a chart review and electronic health record (EHR) data abstraction. The extent to which trial care processes influence surrogate and ICU team member outcomes will be investigated by conducting surveys. Additionally, semi-structured interviews will be conducted with surrogates and ICU team members to investigate how time-limited trial processes work.

The hypothesis is that optimal time-limited trial delivery will reduce intensive care unit length of stay for patients with acute respiratory failure and improve the intensive care unit experiences for their families and clinicians.

03

Conditions studied

  • Acute Respiratory Failure
  • Mechanical Ventilation
  • Life-Supporting Treatments
  • Communication
  • Decision Making
  • Critical Care
  • Palliative Care

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be selected from patients who are admitted to an intensive care unit (ICU) at the University of Wisconsin Hospital, UnityPoint Health - Meriter Hospital, Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, or Northwestern Memorial Hospital. Surrogate participants will be the primary surrogate/s for an eligible patient, and ICU Team Member participants will be members of the hospital staff providing care for an eligible patient.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants

  • Adult (age ≥ 18 years)
  • Acute respiratory failure:

    • Hypoxemic (low level of oxygen in the blood) or
    • Hypercapnic (high level of carbon dioxide in the blood)
  • Receiving invasive mechanical ventilation (patient needs a breathing machine to help them breathe)

Surrogates

  • The main person/s (primary surrogate/s, also known as legally authorized representative/s) who are making medical decisions on behalf of an eligible patient

    • Will be identified by the treating ICU team according to established legal and ethical standards

ICU Team Members

  • A member of the interprofessional hospital staff that is caring for an eligible patient

    • Team members may include advanced practice providers (nurse practitioners/ physicians assistants), case managers, chaplains, dietitians, nurses, pharmacists, physical and occupational therapists, physicians (attending/fellow/resident), respiratory therapists, and social workers.

Exclusion criteria

Exclusion Criteria:

Participants

  • Participant or their legally authorized representative declines participation or opts-out of data collection

Surrogates

  • Cannot complete surveys and interviews in English or Spanish
  • Declines participation

ICU Team Members

  • Opts out of study participation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7,818 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants

    Participants will be selected from patients who are admitted to an intensive care unit (ICU) at the University of Wisconsin Hospital, UnityPoint Health - Meriter Hospital, Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, or Northwestern Memorial Hospital.

  • Surrogates

    Surrogate participants will be the primary surrogate/s for an eligible patient.

  • ICU Team Members

    ICU Team Member participants will be members of the hospital staff providing care for an eligible patient.

06

What researchers measure

Primary outcomes

  1. Intensive Care Unit (ICU) length of stay

    Cumulative number of days that participant stays in the intensive care unit.

    Time frame: Through participant study completion, an average of 8 days

  2. Surrogate end-of-life intensive care unit (ICU) experience

    Surrogate end-of-life intensive care unit (ICU) experience will be measured using the Family Satisfaction in the Intensive Care Unit (FS-ICU) questionnaire. The FS-ICU is a 24 item questionnaire that evaluates family members' satisfaction with their intensive care unit experience. Each question is scored on a 5-point scale from 1 (worst) to 5 (best). The total scores are then converted to a scale from 0 to 100, where 0 is the least satisfied and 100 is the most satisfied.

    Time frame: Between 4 and 16 weeks after participant's hospital discharge

  3. Intensive Care Unit (ICU) team acute moral distress

    Intensive Care Unit (ICU) team acute moral distress will be measured using the Moral Distress Thermometer (MDT). The MDT first presents a definition of moral distress, then asks the respondent to rate their distress related to a specific context on a 10-point scale from 0 (none) to 10 (worst possible) moral distress.

    Time frame: Up to 14 days after participant's hospital discharge

  4. Direct observation of intensive care unit (ICU) care

    Direct observations will include observations of interactions that are pertinent to time-limited trials (e.g., daily interprofessional rounds, nursing shift-change handoffs) and family meetings, including both formal (e.g., in a private conference room) or informal (e.g., on medical rounds or at the bedside) discussions between members of the ICU team, surrogates, patients (if able), and other family members. Observations will be documented using field notes, and family meetings will be audio-recorded and transcribed verbatim. Qualitative analysis of field notes and written transcripts will be done to look for themes and trends that emerge from the data.

    Time frame: Through participant study completion, an average of 8 days

Secondary outcomes

  1. In-hospital mortality

    A participant death occurring during the hospital stay.

    Time frame: Through participant study completion, an average of 8 days

  2. Length of mechanical ventilation

    Cumulative number of days that participant receives invasive mechanical ventilation.

    Time frame: Through participant study completion, an average of 8 days

  3. Surrogate anxiety and depression

    Surrogate anxiety and depression will be measured using the Hospital Anxiety and Depression Scale (HADS), a self-rated scale that aims to measure symptoms of anxiety and depression. The HADS has 14 total items, 7 items measuring anxiety and 7 items measuring depression. Each item is scored on a 4-point Likert scale where scores range from 0 (less anxious or depressed) to 3 (more anxious or depressed).

    Time frame: Between 4 and 16 weeks after participant's hospital discharge

  4. Patient and family centeredness of care

    Patient and family centeredness of care will be measured using the Modified Patient Perceived Patient-Centeredness of Care (PPPC) Scale. The PPPC has 12 total items with a score range of 0 - 100, with higher scores indicating greater patient-centered care.

    Time frame: Between 4 and 16 weeks after participant's hospital discharge

  5. Surrogate Heard and Understood Measure

    The Heard and Understood Measure evaluates the degree to which the surrogate felt heard and understood. This measure has one item with 5 categorical response choices which range from feeling not at all to completely heard and understood by the doctors, nurses and staff in the ICU. Results are summarized by participant counts for each choice.

    Time frame: Between 4 and 16 weeks after participant's hospital discharge

  6. Surrogate decisional regret

    Surrogate decisional regret will be measured using the Decision Regret Scale (DRS) that measures distress or remorse after a health care decision. The DRS has 5 total items scored on a 5-point Likert scale where scores range from 1 (strongly agree) to 4 (strongly disagree). A higher score indicates more regret.

    Time frame: Between 4 and 16 weeks after participant's hospital discharge

  7. Real-time semi-structured qualitative interviews (Surrogate experience)

    Serial, real-time interviews will be conducted following an interview guide that will be iteratively revised as necessary during data collection, according to methodological standards of qualitative interview research. The interviews will be audio-recorded and transcribed verbatim.

    Time frame: Between participant ICU admission and ICU discharge, an average of 8 days

  8. Semi-structured qualitative interviews (Surrogate experience)

    Interviews will be conducted following an interview guide that will be iteratively revised as necessary during data collection, according to methodological standards of qualitative interview research. Surrogate interviews will also use an adapted form of chart-stimulated recall, a case-based interviewing method using prompts to help participants remember and reflect on past events. The interviews will be audio-recorded and transcribed verbatim.

    Time frame: Between 4 and 16 weeks after participant's hospital discharge

  9. Structured qualitative interviews (ICU team members experience)

    Brief, real-time structured interviews will collect team members' knowledge, understanding, and approval of time-limited trials for patients in their care.

    Time frame: Between participant ICU admission and ICU discharge, an average of 8 days

  10. Semi-structured qualitative interviews (ICU team members experience)

    Semi-structured interviews will be conducted following an interview guide that will be iteratively revised as necessary during data collection, according to methodological standards of qualitative interview research. Interviews will also use an adapted form of chart-stimulated recall, a case-based interviewing method using prompts to help participants remember and reflect on past events. The interviews will be audio-recorded and transcribed verbatim.

    Time frame: Up to 4 weeks after participant's hospital discharge

07

Study locations

5 sites
08

References and documents

Publications

  • Kruser JM, Wiegmann DA, Nadig NR, Secunda KE, Hanlon BM, Moy JX, Ahmad A, Campbell EG, Donnelly HK, Martinez FJ, Polley M, Orhan C, Korth E, Stalter LN, Rowe TJ, Wu AL, Viglianti EM, Eisinger EC, Nguyen O, Halpern SD, Clapp JT. Optimising time-limited trials in acute respiratory failure: a multicentre focused ethnography protocol. BMJ Open. 2025 Dec 14;15(12):e106483. doi: 10.1136/bmjopen-2025-106483. PubMed 41397749 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2028, 50 months after the start.

Of 51 non-industry observational studies under Communication, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 61. This study's planned 50 months is above that.

Counting every sponsor, half of 53 studies reached it within 25 months; a quarter within 9 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 18, 2023
StartActual
Jan 17, 2024
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06042621
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Jan 17, 2024
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Feb 5, 2026

Study contacts

Jacqueline M Kruser, MD, MS
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion